SCHEMBL2879390

SCHEMBL2879390

O=C(c1ccc(Cn2ncc3ccccc32)cc1)C1CCCN1[C@H]1CCNC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 3/20 0.42
▸ TSHR P16473 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ CFD P00746 1/20 0.38
▸ ADRA2A P08913 1/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ KMO O15229 1/20 0.35
▸ CDK9 P50750 1/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ POLB P06746 3/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1814722 0.84 KHK (0.44) CFDGAAKHK
SCHEMBL2884746 0.83 HRH3 (0.51) KMT2APOLBHRH3
SCHEMBL4764592 0.80 HRH3 (0.54) RAB9AHRH3
SCHEMBL3797395 0.79 HRH3 (0.46) MEN1ALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL4765934 0.79 MGLL (0.40) ALDH1A1KDM4E
SCHEMBL4792764 0.79 ADAM17 (0.46) L3MBTL1MEN1MAPTKMT2AHRH3
SCHEMBL1813625 0.76 SLC6A4 (0.37) MAPTHRH3
SCHEMBL4013186 0.76 SLC6A4 (0.37) MAPTHRH3
SCHEMBL4889725 0.76 KCNH2 (0.42) ALDH1A1SMN1; SMN2HRH3GAAHTT
SCHEMBL4724233 0.74 HPGD (0.54) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 — — US claimed
EP-1994022-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2008-11-26 — — EP claimed
WO-2007108936-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2007-09-27 — — WO claimed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 — — US claimed
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 — — US disclosed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists HNMT, HRH4, HRH3 RECQL 1694/4885TSHR 620/4885L3MBTL1 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback